[{"indications": "Indications\u00a0see under dose; Crohn\u2019s disease [unlicensed\r\nindication] (section 1.5.3); malignant disease (section 8.1.3); psoriasis (section 13.5.3)", "name": "METHOTREXATE - DRUGS AFFECTING THE IMMUNE RESPONSE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Drugs affecting the immune response", "METHOTREXATE"], "cautions": "Cautions\u00a0section 8.1; see Monitoring, Blood Count, Liver\r\nToxicity, and Pulmonary Toxicity below; extreme caution\r\nin blood disorders (avoid if severe); peptic\r\nulceration, ulcerative colitis, diarrhoea and ulcerative\r\nstomatitis (withdraw if stomatitis develops\u2014may be first sign of gastro-intestinal toxicity); risk of accumulation\r\nin pleural effusion or ascites\u2014drain before treatment; acute porphyria (section 9.8.2); interactions: see below and Appendix 1 (methotrexate)MonitoringIn view of reports of blood dyscrasias (including fatalities)\r\nand liver cirrhosis with low-dose methotrexate patients\r\nshould:have full blood count and renal and liver\r\nfunction tests before starting treatment and repeated every 1\u20132 weeks\r\nuntil therapy stabilised, thereafter patients should be monitored\r\nevery 2\u20133 months(1)be advised to report all symptoms and signs\r\nsuggestive of infection, especially sore throatTreatment with folinic acid (as calcium folinate, section 8.1) may be\r\nrequired in acute toxicityBlood count\u00a0Bone marrow suppression can occur\r\nabruptly; factors likely to increase toxicity include advanced age, renal impairment, and concomitant use with another anti-folate drug (e.g. trimethoprim). A clinically significant drop in white cell\r\ncount or platelet count calls for immediate withdrawal of methotrexate and introduction of supportive therapyLiver toxicity\u00a0Liver cirrhosis reported. Treatment\r\nshould not be started or should be discontinued if any abnormality\r\nof liver function tests or liver biopsy is present or develops during\r\ntherapy. Abnormalities can return to normal within 2\r\nweeks after which treatment may be recommenced if judged appropriatePulmonary toxicity\u00a0Pulmonary toxicity\r\nmay be a special problem in rheumatoid arthritis (patient to seek\r\nmedical attention if dyspnoea, cough or fever); monitor\r\nfor symptoms at each visit\u2014discontinue if pneumonitis suspected.Aspirin and other NSAIDs\u00a0If aspirin or other NSAIDs are given concurrently the dose\r\nof methotrexate should be carefully monitored. Patients should be advised to avoid self-medication with over-the-counter aspirin or ibuprofen", "side-effects": "Side-effects\u00a0section 8.1; also anorexia, abdominal discomfort,\r\ndyspepsia, gastro-intestinal ulceration and bleeding, diarrhoea, toxic\r\nmegacolon, hepatotoxicity (see Cautions above); hypotension, pericarditis,\r\npericardial tamponade; pulmonary oedema, pleuritic pain, pulmonary\r\nfibrosis, interstitial pneumonitis (see also Pulmonary Toxicity above);\r\nanaphylactic reactions, urticaria; dizziness, chills, fever, drowsiness,\r\ninsomnia, malaise, headache, mood changes, neurotoxicity, confusion,\r\nparaesthesia; precipitation of diabetes; menstrual disturbances, vaginitis,\r\ncystitis, reduced libido, impotence; blood disorders; haematuria,\r\ndysuria, renal failure; osteoporosis, arthralgia, myalgia, vasculitis;\r\nconjunctivitis, visual disturbance; rash, pruritus, Stevens-Johnson\r\nsyndrome, toxic epidermal necrolysis, photosensitivity, changes in\r\nnail and skin pigmentation, telangiectasia, acne, furuncolosis, ecchymosis;\r\ninjection-site reactions", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/130052.htm", "doses": ["Moderate to severe active rheumatoid arthritis, by mouth, adult over 18 years,\r\n7.5\u00a0mg once weekly, adjusted according to response; max. weekly dose\r\n20\u00a0mg", "Severe active rheumatoid arthritis, by subcutaneous or by intramuscular or by intravenous injection, adult over 18 years, 7.5\u00a0mg once weekly, increased according to response\r\nby 2.5\u00a0mg weekly; max. weekly dose 25\u00a0mg", "child under 18 years see BNF for Children", "Note that the above dose is a weekly dose.\r\nTo avoid error with low-dose methotrexate, it is recommended that:", "the patient is carefully advised of the dose and frequency and the reason for taking methotrexate\r\nand any other prescribed medicine (e.g. folic acid);", "only one strength of methotrexate tablet (usually 2.5\r\nmg) is prescribed and dispensed;", "the prescription and the dispensing label clearly show\r\nthe dose and frequency of methotrexate administration;", "the patient is warned to report immediately the onset\r\nof any feature of blood disorders (e.g. sore throat, bruising, and\r\nmouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort,\r\nand dark urine), and respiratory effects (e.g. shortness of breath).", "Methotrexate treatment\r\nbooklets should be issued where appropriate, and are available for\r\npurchase from:", "GP practices can obtain supplies through their\r\nPrimary Care Trust (PCT) or Agency stores.", "NHS Hospitals can order supplies from www.nhsforms.co.uk or by emailing nhsforms@mmm.com.", "These booklets include advice for adults taking oral methotrexate\r\nfor inflammatory conditions, and a section for recording results of\r\nblood tests and dosage information."], "pregnancy": "Pregnancy\u00a0avoid (teratogenic; fertility may be reduced during\r\ntherapy but this may be reversible); effective contraception required\r\nduring and for at least 3 months after treatment in men or women;\r\nsee also section 8.1"}, {"indications": "Indications\u00a0see under Inflammatory Bowel Disease; malignant disease (section 8.1.3); rheumatoid arthritis (section 10.1.3); psoriasis (section 13.5.3)", "name": "METHOTREXATE - CHRONIC BOWEL DISORDERS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.3 Drugs affecting the immune response", "METHOTREXATE"], "cautions": "Cautions\u00a0section 10.1.3", "side-effects": "Side-effects\u00a0section 10.1.3", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201305.htm", "doses": ["By intramuscular injection, severe Crohn\u2019s\r\ndisease [unlicensed indication], adult over 18 years, induction of remission, 25\u00a0mg once weekly; maintenance,\r\n15\u00a0mg once weekly", "By mouth, maintenance of remission of severe\r\nCrohn\u2019s disease [unlicensed indication], adult over 18 years, 10\u201325\u00a0mg once weekly", "Note that the above dose is a weekly dose.\r\nTo avoid error with low-dose methotrexate, it is recommended that:", "the patient is carefully advised of the dose and frequency and the reason for taking methotrexate\r\nand any other prescribed medicine (e.g. folic acid);", "only one strength of methotrexate tablet (usually 2.5\u00a0mg)\r\nis prescribed and dispensed;", "the prescription and the dispensing label clearly show\r\nthe dose and frequency of methotrexate administration;", "the patient is warned to report immediately the onset\r\nof any feature of blood disorders (e.g. sore throat, bruising, and\r\nmouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort,\r\nand dark urine), and respiratory effects (e.g. shortness of breath)."], "pregnancy": "Pregnancy\u00a0section 10.1.3"}, {"indications": "Indications\u00a0\n(From 8.1.3 Antimetabolites: British National Formulary)\nMethotrexate inhibits the enzyme dihydrofolate reductase, essential for the synthesis of purines and pyrimidines. It is given by mouth, intravenously, intramuscularly, or intrathecally.Methotrexate is used as maintenance therapy for childhood acute lymphoblastic leukaemia. Other uses include choriocarcinoma, non-Hodgkin\u2019s lymphoma, and a number of solid tumours. Intrathecal methotrexate is used in the CNS prophylaxis of childhood acute lymphoblastic leukaemia, and as a therapy for established meningeal cancer or lymphoma.Methotrexate causes myelosuppression, mucositis, and rarely pneumonitis. It is contra-indicated in significant renal impairment because it is excreted primarily by the kidney. It is also contra-indicated in patients with severe hepatic impairment. It should also be avoided in the presence of significant pleural effusion or ascites because it can accumulate in these fluids, and its subsequent return to the circulation may cause myelosuppression. Systemic toxicity may follow intrathecal administration and blood counts should be carefully monitored.Folinic acid (section 8.1) following methotrexate administration helps to prevent methotrexate-induced mucositis or myelosuppression. and under Dose; Crohn\u2019s disease [unlicensed indication] (%s\n(From METHOTREXATE: British National Formulary)\nMETHOTREXATE); rheumatoid arthritis (%s\n(From 10.1.3 Drugs that suppress the rheumatic disease process: British National Formulary)\n10.1.3 Drugs that suppress the rheumatic disease process); psoriasis\r\n(%s\n(From 13.5.2 Preparations for psoriasis: British National Formulary)\n13.5.2 Preparations for psoriasis)", "name": "METHOTREXATE - ANTIMETABOLITES", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.3 Antimetabolites"], "cautions": "Cautions\u00a0see section 8.1, notes above and section 10.1.3; interactions: Appendix 1 (methotrexate)", "side-effects": "Side-effects\u00a0see section 8.1, notes above and section 10.1.3", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4737.htm", "doses": ["By mouth, leukaemia in children (maintenance),\r\n15\u00a0mg/m2 weekly in combination with other drugs", "Note that the above dose is a weekly dose.", "By intravenous injection or infusion, or by intra-arterial\r\ninfusion, or by intramuscular injection, or intrathecal administration,\r\nconsult product literature"], "pregnancy": "Pregnancy\u00a0avoid (teratogenic; fertility may be reduced during\r\ntherapy but this may be reversible); manufacturer advises effective\r\ncontraception during and for at least 3 months after treatment in\r\nmen or women; see also Pregnancy and Reproductive\r\nFunction"}, {"indications": "Indications\u00a0see under dose; Crohn\u2019s disease [unlicensed\r\nindication] (section 1.5.3); malignant disease (section 8.1.3); psoriasis (section 13.5.3)", "name": "METHOTREXATE Parenteral preparations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Drugs affecting the immune response", "METHOTREXATE", "Parenteral preparations"], "cautions": "Cautions\u00a0section 8.1; see Monitoring, Blood Count, Liver\r\nToxicity, and Pulmonary Toxicity below; extreme caution\r\nin blood disorders (avoid if severe); peptic\r\nulceration, ulcerative colitis, diarrhoea and ulcerative\r\nstomatitis (withdraw if stomatitis develops\u2014may be first sign of gastro-intestinal toxicity); risk of accumulation\r\nin pleural effusion or ascites\u2014drain before treatment; acute porphyria (section 9.8.2); interactions: see below and Appendix 1 (methotrexate)MonitoringIn view of reports of blood dyscrasias (including fatalities)\r\nand liver cirrhosis with low-dose methotrexate patients\r\nshould:have full blood count and renal and liver\r\nfunction tests before starting treatment and repeated every 1\u20132 weeks\r\nuntil therapy stabilised, thereafter patients should be monitored\r\nevery 2\u20133 months(1)be advised to report all symptoms and signs\r\nsuggestive of infection, especially sore throatTreatment with folinic acid (as calcium folinate, section 8.1) may be\r\nrequired in acute toxicityBlood count\u00a0Bone marrow suppression can occur\r\nabruptly; factors likely to increase toxicity include advanced age, renal impairment, and concomitant use with another anti-folate drug (e.g. trimethoprim). A clinically significant drop in white cell\r\ncount or platelet count calls for immediate withdrawal of methotrexate and introduction of supportive therapyLiver toxicity\u00a0Liver cirrhosis reported. Treatment\r\nshould not be started or should be discontinued if any abnormality\r\nof liver function tests or liver biopsy is present or develops during\r\ntherapy. Abnormalities can return to normal within 2\r\nweeks after which treatment may be recommenced if judged appropriatePulmonary toxicity\u00a0Pulmonary toxicity\r\nmay be a special problem in rheumatoid arthritis (patient to seek\r\nmedical attention if dyspnoea, cough or fever); monitor\r\nfor symptoms at each visit\u2014discontinue if pneumonitis suspected.Aspirin and other NSAIDs\u00a0If aspirin or other NSAIDs are given concurrently the dose\r\nof methotrexate should be carefully monitored. Patients should be advised to avoid self-medication with over-the-counter aspirin or ibuprofen", "side-effects": "Side-effects\u00a0section 8.1; also anorexia, abdominal discomfort,\r\ndyspepsia, gastro-intestinal ulceration and bleeding, diarrhoea, toxic\r\nmegacolon, hepatotoxicity (see Cautions above); hypotension, pericarditis,\r\npericardial tamponade; pulmonary oedema, pleuritic pain, pulmonary\r\nfibrosis, interstitial pneumonitis (see also Pulmonary Toxicity above);\r\nanaphylactic reactions, urticaria; dizziness, chills, fever, drowsiness,\r\ninsomnia, malaise, headache, mood changes, neurotoxicity, confusion,\r\nparaesthesia; precipitation of diabetes; menstrual disturbances, vaginitis,\r\ncystitis, reduced libido, impotence; blood disorders; haematuria,\r\ndysuria, renal failure; osteoporosis, arthralgia, myalgia, vasculitis;\r\nconjunctivitis, visual disturbance; rash, pruritus, Stevens-Johnson\r\nsyndrome, toxic epidermal necrolysis, photosensitivity, changes in\r\nnail and skin pigmentation, telangiectasia, acne, furuncolosis, ecchymosis;\r\ninjection-site reactions", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/215543.htm", "doses": ["Moderate to severe active rheumatoid arthritis, by mouth, adult over 18 years,\r\n7.5\u00a0mg once weekly, adjusted according to response; max. weekly dose\r\n20\u00a0mg", "Severe active rheumatoid arthritis, by subcutaneous or by intramuscular or by intravenous injection, adult over 18 years, 7.5\u00a0mg once weekly, increased according to response\r\nby 2.5\u00a0mg weekly; max. weekly dose 25\u00a0mg", "child under 18 years see BNF for Children", "Note that the above dose is a weekly dose.\r\nTo avoid error with low-dose methotrexate, it is recommended that:", "the patient is carefully advised of the dose and frequency and the reason for taking methotrexate\r\nand any other prescribed medicine (e.g. folic acid);", "only one strength of methotrexate tablet (usually 2.5\r\nmg) is prescribed and dispensed;", "the prescription and the dispensing label clearly show\r\nthe dose and frequency of methotrexate administration;", "the patient is warned to report immediately the onset\r\nof any feature of blood disorders (e.g. sore throat, bruising, and\r\nmouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort,\r\nand dark urine), and respiratory effects (e.g. shortness of breath).", "Methotrexate treatment\r\nbooklets should be issued where appropriate, and are available for\r\npurchase from:", "GP practices can obtain supplies through their\r\nPrimary Care Trust (PCT) or Agency stores.", "NHS Hospitals can order supplies from www.nhsforms.co.uk or by emailing nhsforms@mmm.com.", "These booklets include advice for adults taking oral methotrexate\r\nfor inflammatory conditions, and a section for recording results of\r\nblood tests and dosage information.", "Name[Ebetrex\u00ae (Sandoz) ] Injection, prefilled syringe, methotrexate\r\n(as disodium salt) 10\u00a0mg/mL, net price 0.75\u00a0mL (7.5\u00a0mg) = \u00a314.78,\r\n1\u00a0mL (10\u00a0mg) = \u00a315.21, 1.5\u00a0mL (15\u00a0mg) = \u00a316.49; 20\u00a0mg/mL, 1\u00a0mL (20\u00a0mg)\r\n= \u00a317.75, 1.25\u00a0mL (25\u00a0mg) = \u00a318.39, 1.5\u00a0mL (30\u00a0mg) = \u00a320.70"], "pregnancy": "Pregnancy\u00a0avoid (teratogenic; fertility may be reduced during\r\ntherapy but this may be reversible); effective contraception required\r\nduring and for at least 3 months after treatment in men or women;\r\nsee also section 8.1"}, {"indications": "Indications\u00a0severe psoriasis unresponsive to conventional\r\ntherapy (specialist use only); Crohn\u2019s disease (section 1.5.3); malignant disease (section 8.1.3); rheumatoid arthritis (section 10.1.3)", "name": "METHOTREXATE - PREPARATIONS FOR ECZEMA AND PSORIASIS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.3 Drugs affecting the immune response"], "cautions": "Cautions\u00a0section 10.1.3; also photosensitivity\u2014psoriasis\r\nlesions aggravated by UV radiation (skin ulceration reported)", "side-effects": "Side-effects\u00a0section 10.1.3", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/6002.htm", "doses": ["By mouth or by\r\nintramuscular or  intravenous  or subcutaneous injection, 2.5\u201310\u00a0mg\r\nonce weekly, increased according to response in steps of 2.5\u20135\u00a0mg\r\nat intervals of at least 1 week; usual dose 7.5\u201315\u00a0mg once weekly;\r\nmax. weekly dose 30\u00a0mg; child 2\u201318\r\nyears see BNF for Children", "Note that the above dose is a weekly dose.\r\nTo avoid error with low dose methotrexate, it is recommended that:", "the patient is carefully advised of the dose and frequency and the reason for taking methotrexate\r\nand any other prescribed medicine (e.g. folic acid);", "only one strength of methotrexate tablet (usually 2.5\u00a0mg) is prescribed and dispensed;", "the prescription and the dispensing label clearly show\r\nthe dose and frequency of methotrexate administration;", "the patient is warned to report immediately the onset\r\nof any feature of blood disorders (e.g. sore throat, bruising, and\r\nmouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort\r\nand dark urine), and respiratory effects (e.g. shortness of breath)."], "pregnancy": "Pregnancy\u00a0section 10.1.3"}, {"indications": "Indications\u00a0\n(From 8.1.3 Antimetabolites: British National Formulary)\nMethotrexate inhibits the enzyme dihydrofolate reductase, essential for the synthesis of purines and pyrimidines. It is given by mouth, intravenously, intramuscularly, or intrathecally.Methotrexate is used as maintenance therapy for childhood acute lymphoblastic leukaemia. Other uses include choriocarcinoma, non-Hodgkin\u2019s lymphoma, and a number of solid tumours. Intrathecal methotrexate is used in the CNS prophylaxis of childhood acute lymphoblastic leukaemia, and as a therapy for established meningeal cancer or lymphoma.Methotrexate causes myelosuppression, mucositis, and rarely pneumonitis. It is contra-indicated in significant renal impairment because it is excreted primarily by the kidney. It is also contra-indicated in patients with severe hepatic impairment. It should also be avoided in the presence of significant pleural effusion or ascites because it can accumulate in these fluids, and its subsequent return to the circulation may cause myelosuppression. Systemic toxicity may follow intrathecal administration and blood counts should be carefully monitored.Folinic acid (section 8.1) following methotrexate administration helps to prevent methotrexate-induced mucositis or myelosuppression. and under Dose; Crohn\u2019s disease [unlicensed indication] (%s\n(From METHOTREXATE: British National Formulary)\nMETHOTREXATE); rheumatoid arthritis (%s\n(From 10.1.3 Drugs that suppress the rheumatic disease process: British National Formulary)\n10.1.3 Drugs that suppress the rheumatic disease process); psoriasis\r\n(%s\n(From 13.5.2 Preparations for psoriasis: British National Formulary)\n13.5.2 Preparations for psoriasis)", "name": "METHOTREXATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.3 Antimetabolites"], "cautions": "Cautions\u00a0see section 8.1, notes above and section 10.1.3; interactions: Appendix 1 (methotrexate)", "side-effects": "Side-effects\u00a0see section 8.1, notes above and section 10.1.3", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4737.htm", "doses": ["By mouth, leukaemia in children (maintenance),\r\n15\u00a0mg/m2 weekly in combination with other drugs", "Note that the above dose is a weekly dose.", "By intravenous injection or infusion, or by intra-arterial\r\ninfusion, or by intramuscular injection, or intrathecal administration,\r\nconsult product literature"], "pregnancy": "Pregnancy\u00a0avoid (teratogenic; fertility may be reduced during\r\ntherapy but this may be reversible); manufacturer advises effective\r\ncontraception during and for at least 3 months after treatment in\r\nmen or women; see also Pregnancy and Reproductive\r\nFunction"}, {"indications": "Indications\u00a0see under dose; Crohn\u2019s disease [unlicensed\r\nindication] (section 1.5.3); malignant disease (section 8.1.3); psoriasis (section 13.5.3)", "name": "METHOTREXATE - DRUGS THAT SUPPRESS THE RHEUMATIC DISEASE PROCESS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Drugs affecting the immune response", "METHOTREXATE"], "cautions": "Cautions\u00a0section 8.1; see Monitoring, Blood Count, Liver\r\nToxicity, and Pulmonary Toxicity below; extreme caution\r\nin blood disorders (avoid if severe); peptic\r\nulceration, ulcerative colitis, diarrhoea and ulcerative\r\nstomatitis (withdraw if stomatitis develops\u2014may be first sign of gastro-intestinal toxicity); risk of accumulation\r\nin pleural effusion or ascites\u2014drain before treatment; acute porphyria (section 9.8.2); interactions: see below and Appendix 1 (methotrexate)MonitoringIn view of reports of blood dyscrasias (including fatalities)\r\nand liver cirrhosis with low-dose methotrexate patients\r\nshould:have full blood count and renal and liver\r\nfunction tests before starting treatment and repeated every 1\u20132 weeks\r\nuntil therapy stabilised, thereafter patients should be monitored\r\nevery 2\u20133 months(1)be advised to report all symptoms and signs\r\nsuggestive of infection, especially sore throatTreatment with folinic acid (as calcium folinate, section 8.1) may be\r\nrequired in acute toxicityBlood count\u00a0Bone marrow suppression can occur\r\nabruptly; factors likely to increase toxicity include advanced age, renal impairment, and concomitant use with another anti-folate drug (e.g. trimethoprim). A clinically significant drop in white cell\r\ncount or platelet count calls for immediate withdrawal of methotrexate and introduction of supportive therapyLiver toxicity\u00a0Liver cirrhosis reported. Treatment\r\nshould not be started or should be discontinued if any abnormality\r\nof liver function tests or liver biopsy is present or develops during\r\ntherapy. Abnormalities can return to normal within 2\r\nweeks after which treatment may be recommenced if judged appropriatePulmonary toxicity\u00a0Pulmonary toxicity\r\nmay be a special problem in rheumatoid arthritis (patient to seek\r\nmedical attention if dyspnoea, cough or fever); monitor\r\nfor symptoms at each visit\u2014discontinue if pneumonitis suspected.Aspirin and other NSAIDs\u00a0If aspirin or other NSAIDs are given concurrently the dose\r\nof methotrexate should be carefully monitored. Patients should be advised to avoid self-medication with over-the-counter aspirin or ibuprofen", "side-effects": "Side-effects\u00a0section 8.1; also anorexia, abdominal discomfort,\r\ndyspepsia, gastro-intestinal ulceration and bleeding, diarrhoea, toxic\r\nmegacolon, hepatotoxicity (see Cautions above); hypotension, pericarditis,\r\npericardial tamponade; pulmonary oedema, pleuritic pain, pulmonary\r\nfibrosis, interstitial pneumonitis (see also Pulmonary Toxicity above);\r\nanaphylactic reactions, urticaria; dizziness, chills, fever, drowsiness,\r\ninsomnia, malaise, headache, mood changes, neurotoxicity, confusion,\r\nparaesthesia; precipitation of diabetes; menstrual disturbances, vaginitis,\r\ncystitis, reduced libido, impotence; blood disorders; haematuria,\r\ndysuria, renal failure; osteoporosis, arthralgia, myalgia, vasculitis;\r\nconjunctivitis, visual disturbance; rash, pruritus, Stevens-Johnson\r\nsyndrome, toxic epidermal necrolysis, photosensitivity, changes in\r\nnail and skin pigmentation, telangiectasia, acne, furuncolosis, ecchymosis;\r\ninjection-site reactions", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128179.htm", "doses": ["Moderate to severe active rheumatoid arthritis, by mouth, adult over 18 years,\r\n7.5\u00a0mg once weekly, adjusted according to response; max. weekly dose\r\n20\u00a0mg", "Severe active rheumatoid arthritis, by subcutaneous or by intramuscular or by intravenous injection, adult over 18 years, 7.5\u00a0mg once weekly, increased according to response\r\nby 2.5\u00a0mg weekly; max. weekly dose 25\u00a0mg", "child under 18 years see BNF for Children", "Note that the above dose is a weekly dose.\r\nTo avoid error with low-dose methotrexate, it is recommended that:", "the patient is carefully advised of the dose and frequency and the reason for taking methotrexate\r\nand any other prescribed medicine (e.g. folic acid);", "only one strength of methotrexate tablet (usually 2.5\r\nmg) is prescribed and dispensed;", "the prescription and the dispensing label clearly show\r\nthe dose and frequency of methotrexate administration;", "the patient is warned to report immediately the onset\r\nof any feature of blood disorders (e.g. sore throat, bruising, and\r\nmouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort,\r\nand dark urine), and respiratory effects (e.g. shortness of breath).", "Methotrexate treatment\r\nbooklets should be issued where appropriate, and are available for\r\npurchase from:", "GP practices can obtain supplies through their\r\nPrimary Care Trust (PCT) or Agency stores.", "NHS Hospitals can order supplies from www.nhsforms.co.uk or by emailing nhsforms@mmm.com.", "These booklets include advice for adults taking oral methotrexate\r\nfor inflammatory conditions, and a section for recording results of\r\nblood tests and dosage information."], "pregnancy": "Pregnancy\u00a0avoid (teratogenic; fertility may be reduced during\r\ntherapy but this may be reversible); effective contraception required\r\nduring and for at least 3 months after treatment in men or women;\r\nsee also section 8.1"}]